Net Loss Per Share (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of basic and diluted net loss per share

Basic and diluted net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd. was calculated as follows:


	Three Months Ended March 31,
	2022		2021
Numerator:
Net loss	$	(116,897)	$	(265,328)
Net loss attributable to non-controlling interests	498		360
Deemed dividend upon repurchase of preferred shares in consolidated subsidiary (1)	(92,673)		—
Net loss attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.	$	(209,072)	$	(264,968)
Denominator:
Weighted average common shares outstanding—basic and diluted	70,332,274		62,040,715
Net loss per share attributable to common shareholders of Biohaven Pharmaceutical Holding Company Ltd.—basic and diluted	$	(2.97)	$	(4.27)

(1) As part of the BioShin Merger Agreement, the Company repurchased the 15,384,613 BioShin Series A Preferred Shares previously classified as mezzanine equity on the condensed consolidated balance sheet in exchange for 1,232,629 shares of the Company with a fair value of $152,673 (see Note 9 for further detail).

Schedule of potentially anti-dilutive securities excluded from calculation of diluted net loss per share

The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common

shareholders for the periods indicated because including them would have had an anti-dilutive effect:


	As of March 31,
	2022	2021
Options to purchase common shares	8,282,312	8,549,583
Warrants to purchase common shares	100,000	106,751
Restricted share units and performance share units	1,707,606	1,045,519
Total	10,089,918	9,701,853